Recombinant mcsB protein

In the field of biotechnology, protein research and production are key supports for cutting-edge exploration. As an innovator in the industry, Apti relies on its outstanding research and development capabilities to successfully develop over 1000 new proteins every year, continuously breaking through in the field of recombinant proteins. During the production process of recombinant proteins, Apti has accumulated rich and mature experience. From complex transmembrane proteins, to enzymes with specific catalytic functions, kinases involved in signal transduction, to viral antigens used in immune research, Aptamil can achieve efficient and stable production. This achievement cannot be achieved without the powerful technological platform of Apti. We have constructed a diversified recombinant protein expression system that works in synergy with insect cells, mammalian cells, and prokaryotic protein expression systems. Different expression systems have their own advantages, which can meet the diverse needs of different customers for the activity, yield, cost, and other aspects of recombinant proteins, thereby providing high-quality and low-cost active recombinant proteins. Apti not only provides products, but also a one-stop solution from the source to the end. From the initial gene synthesis, precise construction of gene sequences that meet the requirements, to vector construction, creating a suitable environment for protein expression, and then to protein expression and purification, every step is strictly controlled. We fully respect the personalized needs of our customers and tailor exclusive solutions for the selection of expression/purification labels, determination of expression hosts, and other aspects. At the same time, Apti is equipped with multiple purification systems to meet the purification needs of different characteristic proteins. This flexibility and professionalism greatly improve the success rate of protein expression and purification, enabling clients' research projects to proceed smoothly and helping every researcher on the path of biotechnology exploration to achieve success.

Apti Biotech independently develops and establishes a comprehensive technology platform for recombinant protein production and antibody development, including: Mammalian cell expression platform: Utilizing mammalian cells to precisely modify proteins, producing recombinant proteins similar to natural proteins for drug development, cell therapy, and other applications. Hybridoma development platform: stable hybridoma cell lines secreting monoclonal antibodies are screened through cell fusion, and the optimized technology enhances antibody affinity and specificity, making it applicable in fields such as disease diagnosis and immunotherapy. Single B cell screening platform: FACS uses fluorescent labeling and flow cytometry to quickly sort specific B cells; Beacon ® Based on microfluidic technology, capture and analyze B cells at the single-cell level, explore antibody diversity, and shorten the development cycle. With these platforms, Apti Biotech provides customers with high-quality reagents and professional CRO technology services, promoting the development of biotechnology.

Apti Biotech has extensive experience in the development of recombinant and natural proteins, with over 20000 cases of recombinant protein development. In the application of the four major recombinant protein expression platforms, Apti Biotech not only has extensive experience, but also has accumulated detailed successful cases. We can customize and optimize experimental plans to meet the industrial production needs of our customers. Through small-scale exploration, process amplification, and condition optimization, the recombinant protein gene sequence is optimized, and various conditions are comprehensively explored to accurately find the production method that best meets customer needs. In addition, the company is equipped with its own downstream verification platform, which can conduct systematic quality testing and performance testing on recombinant proteins, covering protein interaction testing, activity verification, endotoxin verification, etc., to comprehensively ensure product quality. KAMED Biotech also attaches great importance to the development of protein technology, ensuring that the produced proteins have the required purity, stability, and biological activity, which plays a key role in ensuring the safety and effectiveness of drugs, and jointly promotes the development of the industry with Aptamil Biotech.